Genomic Testing For Treatment Planning For Early Breast Cancer

  Address - Slovenia

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 101577385

  Document Type - Tender Notices

Description - Description: Genomic tests OncotypeDX and Mammaprint, in the 3rd phase of clinical studies (TailorX and Mindact), demonstrated the clinical utility of the 1st level in adjuvant systemic treatment with endocrine therapy and without chemotherapy.Based on the results, both tests are included in the main international clinical guidelines. In the National Comprehensive Cancer Center Network (NCCN) clinical guidelines, both tests are classified as level 1 of clinical utility.Based on the above, the client submits a public order for the subject of order no. JN-0040/2024 for "Genomic testing for early breast cancer treatment planning", in two lots, namely:Lot 1: Oncotype DX® Assay (Exact Sciences)L

Gt Ref Id - 101577385

Deadline - Jan 24, 2025